The 4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit

We’re looking forward to joining industry leaders, R&D teams and investors at Oppenheimer’s 4th Annual Targeted Radiopharmaceutical Therapies Summit in New York on 17 September.

Radioligand therapy is one of the fastest-moving areas in oncology, and it puts imaging at the center of the development story — from patient selection and target expression through to response assessment and dosimetry. Getting that imaging right, and getting it independently and consistently read across sites, is where trials are won or lost.

Olga Kubassova, Founder & President, and Mike Fisher VP, Business Development & Strategic Partnerships will be attending on behalf of IAG. They’ll be there to talk through the imaging challenges specific to RLT programs — protocol and charter design, blinded independent central review, and quantitative analysis on DYNAMIKA.

If you’re attending and would like to arrange a meeting, get in touch we’d be glad to connect.